公开(公告)号：WO2012000103A8

公开(公告)日：2012-01-05

申请号：PCT/CA2011/000776

申请日：2011-07-04

Applicant: UNIVERSITY HEALTH NETWORK ,  PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

Inventor： PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：WO2020181376A1

公开(公告)日：2020-09-17

申请号：PCT/CA2020/050321

申请日：2020-03-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/18 ,  A61K39/395 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

公开(公告)号：WO2016065461A1

公开(公告)日：2016-05-06

申请号：PCT/CA2015/051024

申请日：2015-10-09

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： LAUFER, Radoslaw ,  NG, Grace ,  BROKX, Richard ,  PAULS, Heinz W. ,  LI, Sze-wan ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

Abstract translation: 本发明是由结构式（I）表示的化合物：（I）; 或其药学上可接受的盐。 这里提供了变量的值。 还包括药物组合物，其包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂以及用结构式（I）的化合物治疗患有癌症的受试者的方法。

公开(公告)号：WO2021207828A1

公开(公告)日：2021-10-21

申请号：PCT/CA2021/050483

申请日：2021-04-12

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  WEI, Xin ,  DUNCAN, Gordon

IPC: A61K31/4436 ,  A61P37/02 ,  C07D495/04

Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.

公开(公告)号：WO2021108918A1

公开(公告)日：2021-06-10

申请号：PCT/CA2020/051668

申请日：2020-12-04

Applicant: UNIVERSITY HEALTH NETWORK ,  BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K31/194 ,  A61P35/02 ,  C07C57/15 ,  C07D413/14

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2020163962A1

公开(公告)日：2020-08-20

申请号：PCT/CA2020/050195

申请日：2020-02-14

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C12N15/13 ,  C12N5/10 ,  C12P21/08

Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

公开(公告)号：WO2019023799A1

公开(公告)日：2019-02-07

申请号：PCT/CA2018/050936

申请日：2018-08-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BRAY, Mark Robert ,  MASON, Jacqueline M. ,  MAK, Tak W. ,  FLETCHER, Graham

IPC: A61K31/519 ,  A61K39/395 ,  A61P35/00 ,  C07D487/04 ,  C07K16/18

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：WO2019023786A1

公开(公告)日：2019-02-07

申请号：PCT/CA2017/050920

申请日：2017-08-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BRAY, Mark Robert ,  MASON, Jacqueline M. ,  MAK, Tak W. ,  FLETCHER, Graham

IPC: A61K31/519 ,  A61K39/395 ,  A61P35/00 ,  A61P37/02 ,  C07D487/04 ,  C07K16/28 ,  C07K16/30

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：WO2015054781A1

公开(公告)日：2015-04-23

申请号：PCT/CA2014/050952

申请日：2014-10-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HEDLEY, David W. ,  LOHSE, Ines ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14

CPC classification number: A61K31/5377 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D403/08 ,  C07D413/14 ,  A61K2300/00

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及通过施用结构式（I）表示的化合物或其药学上可接受的盐来治疗患有胰腺癌的受试者的方法。

公开(公告)号：WO2022187968A1

公开(公告)日：2022-09-15

申请号：PCT/CA2022/050363

申请日：2022-03-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark Robert ,  DUNCAN, Gordon S.

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.